Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion

被引:0
|
作者
Gebbia, V
Mauceri, G
Testa, A
Tirrito, M
Varvara, F
Cucchiara, A
Borsellino, N
Girlando, A
Ferrara, M
Caruso, F
机构
[1] Ctr Catanese Oncol, Div Med Oncol, I-95100 Catania, Italy
[2] Clin Macchiarella, Div Oncol, Palermo, Italy
[3] Clin Torina, Serv Oncol, Palermo, Italy
[4] Ctr Catanese Oncol, Div Radiotherapy, Catania, Italy
[5] Ctr Catanese Oncol, Div Surg Oncol, I-95100 Catania, Italy
关键词
breast cancer; metastases; 5-fluorouracil; levofolinic acid; vinorelbine;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Twenty-four consecutive patients with metastatic breast carcirioma (MBC) refractory to first line chemotherapy 2 were treated with high-dose folinic acid (FA) 100 mg/m(2) diluted in 250 cc of normal saline as 2 2 hour infusion followed by 5-fluorouracil (5FU) 400 mg/m(2) bolus then 5FU 600 mg/m(2) as continuous infusion for 22 hours. This therapy was repeated for 2 consecutive days. Chemotherapy was repeated every 15 days. All enrolled patients were evaluable for objective response. A complete response was achieved in 1 patient (4%) and a partial response in 6 cases (25%) for an overall response rate of 29% (confidence limits 18%-39%). The median duration of objective responses was 8.4+ months (range 3.0+/12.8). Six patients showed no change (25%) with a median duration of 4.0 months 11 patients progressed (46%). A subjective improvemernt in tumor-related symptoms was reported by all responding patients and in 3 patients with no change. Most patients (7/10) with symptomatic bone lesions had a subjective improvement with reduction in analgesic drugs consumption. Objective responses were observed at all sites of disease. In fact, responses were seen in the skin liver lung bore and rodal metastases. The median overall survival was 13.0+ months (range 4.0/16.2+). Over a total of 160 cycles (a mean of 6.6 cycles/patient) grade 1-2 leukopenia was seen in 9 patients (37%) grade 1 thrombocytoperia in 4 patients (17%) and grade 1 anemia in only 2 cases (8%). Grade 3-4 leukopenia or thrombocytopenia were not seen. Phlebitis at the injection vein occurred in 3/10 patients (30%) which refuded to implant a central line. In patients with a central line or a port-a-cath no cases of vascula toxicity were seen. Gastrointestinal toxicity was very mild with 9 patients (37%) suffering from grade 1- 2 nausea/vomiting 6 patients (25%) complaining of grade 1-2 diarrhea and 6 patients with grade 1-2 stomatitis. Hand-foot syndrome was observed in only 1 patient. No cases of grade 3-4 gastrointestinal toxicities have been, observed No cases of cardiotoxicity and/or neurotoxicity were recorded The combination of high-dose FA and 5FU given as 48 hour continuous venous infusion every 2 weeks is active, at least in. terms of objective response rate and tumor related symptoms palliation against anthracycline-refractory MBC These results compare favorably with bolus administration of FA and 5FU or other salvage regimens.
引用
收藏
页码:2289 / 2292
页数:4
相关论文
共 50 条
  • [1] Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: A phase II study
    Gebbia, V
    Borsellino, N
    Testa, A
    Tirrito, M
    Varvara, F
    Cucchiara, A
    Mauceri, G
    Girlando, A
    Ferrara, M
    Caruso, F
    ANTICANCER RESEARCH, 1999, 19 (4C) : 3553 - 3557
  • [2] Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer
    Lombardi, D
    Magri, MD
    Crivellari, D
    Spazzapan, S
    Paolello, C
    De Cicco, M
    Di Lauro, V
    Scuderi, C
    Veronesi, A
    ANNALS OF ONCOLOGY, 2000, 11 (08) : 1041 - 1043
  • [3] CONTINUOUS INTRAVENOUS-INFUSION OF 5-FLUOROURACIL IN THE TREATMENT OF REFRACTORY BREAST-CANCER
    CHANG, AYC
    MOST, C
    PANDYA, KJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1989, 12 (05): : 453 - 455
  • [4] Vinorelbine (VNB) and 5-fluorouracil (5-FU) with levofolinic acid as 48 hour infusion in metastatic breast cancer (MBC) patients: A phase II study
    Bergnolo, Paola
    Cutin, Simona Chiado
    Oliva, Cristiano
    Boglione, Antonella
    Biscardi, Manuela
    Dal Canton, Orietta
    Garetto, Ferdinando
    Pochettino, Paolo
    Comandone, Alessandro
    ANNALS OF ONCOLOGY, 2005, 16 : 15 - 15
  • [5] CONTINUOUS 5-FLUOROURACIL INFUSION IN REFRACTORY CARCINOMA OF THE BREAST
    HANSEN, R
    QUEBBEMAN, E
    BEATTY, P
    RITCH, P
    ANDERSON, T
    JENKINS, D
    FRICK, J
    AUSMAN, R
    BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (02) : 145 - 149
  • [6] ASSOCIATION OF BOLUS TETRAHYDROPYRANYL ADRIAMYCIN AND 120 HOURS CONTINUOUS 5-FLUOROURACIL INFUSION IN PATIENTS WITH METASTATIC BREAST-CANCER
    CHEVALLIER, B
    FUMOLEAU, P
    KERBRAT, P
    MONNIER, A
    ROCHE, H
    GOUDIE, MJ
    HERAIT, P
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 : S40 - S43
  • [7] Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer
    Regazzoni, S
    Pesce, G
    Marini, G
    Cavalli, F
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 1996, 7 (08) : 807 - 813
  • [8] The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer
    Vredenburgh, J
    Fishman, R
    Coniglio, D
    Matters, L
    Elkordy, M
    Ross, M
    Hussein, A
    Rubin, P
    Gilbert, C
    Petros, W
    Peters, WP
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (06): : 543 - 547
  • [9] CONTINUOUS 5-FLUOROURACIL (5-FU) INFUSION IN REFRACTORY CARCINOMA OF THE BREAST
    HANSEN, R
    QUEBBEMAN, E
    RITCH, P
    BEATTY, P
    ANDERSON, T
    JENKINS, D
    FRICK, J
    AUSMAN, R
    CLINICAL RESEARCH, 1986, 34 (04): : A931 - A931
  • [10] SIMULTANEOUS 5-DAY CONTINUOUS INFUSION (CI) OF VINBLASTINE (V) AND 5-FLUOROURACIL (F) FOR THE TREATMENT OF REFRACTORY METASTATIC BREAST-CANCER (MBC)
    FRASCHINI, G
    ESPARZA, L
    TASHIMA, C
    JABBOURY, K
    HORTOBAGYI, G
    ANDERSON, MD
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 196 - 196